Cat. No.: HY-12137

Volasertib

(Synonyms: BI 6727)

38 Cited Publications

Customer Review

Based on 38 publication(s) in Google Scholar

Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models.

For research use only. We do not sell to patients.

Purity: 99.97%
CAS No.: 755038-65-4
Formula: C₃₄H₅₀N₈O₃
Molecular Weight:618.81

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Volasertib Chemical Structure

CAS No.: 755038-65-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (38)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[3]

PLK1

0.87 nM (IC₅₀)

PLK2

5 nM (IC₅₀)

PLK3

56 nM (IC₅₀)

All Polo-like Kinase (PLK) Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	4137 nM Compound: 3; BI 6727	Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
A-427	IC₅₀	91 nM Compound: 44	Antiproliferative activity against human A-427 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay Antiproliferative activity against human A-427 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay	[PMID: 37197456]
A549	IC₅₀	0.08 μM Compound: BI6727; I	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
A549	IC₅₀	206.4 nM Compound: 3; BI 6727	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
DU-145	IC₅₀	<4 nM Compound: 3; BI 6727	Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
Granta-519	EC₅₀	15 nM Compound: Chemicel probe : BI 6727	Antimitotic activity against human Granta-519 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis Antimitotic activity against human Granta-519 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis	[PMID: 19383823]
HCT-116	EC₅₀	23 nM Compound: Chemicel probe : BI 6727	Antimitotic activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis Antimitotic activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis	[PMID: 19383823]
HCT-116	IC₅₀	0.11 μM Compound: BI6727; I	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
HCT-116	IC₅₀	602.4 nM Compound: 3; BI 6727	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
HEK-293T	IC₅₀	1.1 nM Compound: Volasertib	Inhibition of cell growth in HEK293T cells incubated for 72 hrs by CellTiter-blue reagent based assay Inhibition of cell growth in HEK293T cells incubated for 72 hrs by CellTiter-blue reagent based assay	[PMID: 34710325]
HepG2	IC₅₀	<4 nM Compound: 3; BI 6727	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
HL-60	EC₅₀	32 nM Compound: Chemicel probe : BI 6727	Antimitotic activity against human HL-60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis Antimitotic activity against human HL-60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis	[PMID: 19383823]
HT-29	IC₅₀	1133 nM Compound: 3; BI 6727	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
JeKo-1	IC₅₀	<4 nM Compound: 3; BI 6727	Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
K562	IC₅₀	<4 nM Compound: 3; BI 6727	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
KARPAS-299	IC₅₀	<4 nM Compound: 3; BI 6727	Antiproliferative activity against human KARPAS-299 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human KARPAS-299 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
L02	IC₅₀	<4 nM Compound: 3; BI 6727	Antiproliferative activity against human LO2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human LO2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
MCF7	IC₅₀	0.09 μM Compound: BI6727; I	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
MDA-MB-231	IC₅₀	0.11 μM Compound: BI6727; I	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
MDA-MB-231	IC₅₀	1482 nM Compound: 3; BI 6727	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
MM1.S	IC₅₀	4.5 nM Compound: Volasertib	Inhibition of cell growth in human MM1.S cells incubated for 72 hrs by CellTiter-blue reagent based assay Inhibition of cell growth in human MM1.S cells incubated for 72 hrs by CellTiter-blue reagent based assay	[PMID: 34710325]
NCI-H23	IC₅₀	53 nM Compound: 44	Antiproliferative activity against human NCI-H23 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay Antiproliferative activity against human NCI-H23 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay	[PMID: 37197456]
NCI-H460	EC₅₀	21 nM Compound: Chemicel probe : BI 6727	Antimitotic activity against human NCI-H460 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis Antimitotic activity against human NCI-H460 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis	[PMID: 19383823]
PC-3	IC₅₀	0.09 μM Compound: BI6727; I	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
Raji	EC₅₀	11 nM Compound: Chemicel probe : BI 6727	Antimitotic activity against human Raji cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis Antimitotic activity against human Raji cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis	[PMID: 19383823]
SMMC-7721	IC₅₀	77.2 nM Compound: 3; BI 6727	Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
THP-1	EC₅₀	36 nM Compound: Chemicel probe : BI 6727	Antimitotic activity against human THP-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis Antimitotic activity against human THP-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis	[PMID: 19383823]

In Vitro

Volasertib (BI 6727; 0.01-10000 nM; 72 hours) has EC₅₀ values of 11 to 37 nmol/L in multiple cell lines^[1].
Volasertib (10-1000 nM; 24 hours) results accumulation of cells with 4N DNA content, indicative of a cell cycle block in G2-M phase^[1].
Volasertib (100 nM; 24-72 hours) induces cell apoptosis at 48 hours^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

Multiple cell lines
Concentration:

0.01-10000 nM
Incubation Time:

72 hours
Result:

Inhibited proliferation of multiple cell lines derived from various cancer tissues, including carcinomas of the colon (HCT 116, EC₅₀=23 nmol/L) and lung (NCI-H460, EC₅₀=21 nmol/L), melanoma (BRO, EC₅₀=11 nmol/L), and hematopoietic cancers (GRANTA-519, EC₅₀=15 nmol/L; HL-60, EC₅₀=32 nmol/L; THP-1, E₅₀=36 nmol/L and Raji, EC₅₀=37 nmol/L) with EC₅₀ values of 11 to 37 nmol/L.

Apoptosis Analysis^[1]

Cell Line:

NCI-H460 cells
Concentration:

100 nM
Incubation Time:

24, 48, 72 hours
Result:

G2-M arrest at 24 hours was followed by induction of apoptosis at 48 hours.

Cell Cycle Analysis^[1]

Cell Line:

NCI-H460 cells
Concentration:

10, 30, 100, 300, 1000 nM
Incubation Time:

24 hours
Result:

Resulted in accumulation of cells with 4N DNA content, indicative of a cell cycle block in G2-M phase.

In Vivo

Volasertib (BI 6727; A total weekly dose of 50 mg/kg; Oral; once a week, twice a week, or daily; for 40 days) shows comparable efficacy in human colon carcinoma xenograft models^[1].
Volasertib (15, 20, or 25 mg/kg/day; i.v.; 2 consecutive days per week; for 40 days) leads to significant tumor growth delay and even tumor regression in human colon carcinoma xenograft models ^[1].
Volasertib (70 mg/kg given once weekly or 10 mg/kg daily; oral) significantly delays tumor growth in a non-small cell lung carcinoma xenograft model derived from NCI-H460 cells^[1].
Volasertib (a single dose of 40 mg/kg; iv) causes a significant (13-fold) increase in mitotic cells in HCT 116 tumor-bearing nude mice^[1].
Volasertib has high volume of distribution and a long terminal half-life in mice (V_ss=7.6 L/kg, t_1/2=46 h) and rats (V_ss=22 L/kg, t_1/2=54 h)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female BomTac:NMRI-Foxn1^nu mice (Taconic) were grafted s.c. with HCT 116 human colon carcinoma cells (ATCC CCL-247)^[1]
Dosage:

A total weekly dose of 50 mg/kg
Administration:

Oral; once a week, twice a week, or daily; for 40 days
Result:

Showed comparable efficacy and were well tolerated.

Animal Model:

Female BomTac:NMRI-Foxn1^nu mice and male Wistar rats of the strain Crl:WI^[1]
Dosage:

35 mg/kg (mice) or 10 mg/kg (rat) (Pharmacokinetic Analysis)
Administration:

IV 5-minute infusion; a single dose 5-minute infusion
Result:

Had high volume of distribution and a long terminal half-life in mice (V_ss=7.6 L/kg, t_1/2=46 h) and rats (V_ss=22 L/kg, t_1/2=54 h).

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 755038-65-4
Appearance Solid
Molecular Weight 618.81
Formula C₃₄H₅₀N₈O₃
Color Off-white to light yellow
SMILES

O=C(C1=CC=C(C(OC)=C1)NC2=NC=C(N(C3=O)C)C(N([C@@H]3CC)C(C)C)=N2)N[C@H]4CC[C@@H](CC4)N5CCN(CC5)CC6CC6
Synonyms

BI 6727
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (38)

All WBCell Proliferation/Viability AssayIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Cell

Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors. [Abstract]

2025 Jun 26;188(13):3405-3421.e27. PMID: 40300601
Nat Commun

Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability. [Abstract]

2024 Mar 16;15(1):2377. PMID: 38493213

Volasertib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Mar 16;15(1):2377. [Abstract]

Immunoblot of NUDT1 p-S121 in Kelly cells treated with PLK1 shRNA or BI6727 (20 nM, 0, 24, 48 h).
Nat Commun

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. [Abstract]

2020 Aug 13;11(1):4053. PMID: 32792481
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Theranostics

Single-cell analyses reveal evolution mimicry during the specification of breast cancer subtype. [Abstract]

2024 May 19;14(8):3104-3126. PMID: 38855191
Cell Discov

Single-cell profiling reveals molecular basis of malignant phenotypes and tumor microenvironments in small bowel adenocarcinomas. [Abstract]

2022 Sep 14;8(1):92. PMID: 36104333

Volasertib purchased from MedChemExpress. Usage Cited in: Cell Discov. 2022 Sep 14;8(1):92. [Abstract]

Cell survival curve for HUTU-80 cells treated with the indicated inhibitors with Volasertib from 0 to 100 μM (36 h).
J Colloid Interface Sci

In situ generation of anti-leukemia vaccine by immunogenic dual-drug nanomedicine and polymersomal CpG nanoadjuvant. [Abstract]

2025 Jun 9;699(Pt 1):138144. PMID: 40527143
NPJ Precis Oncol

Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study. [Abstract]

2025 Nov 21;9(1):373. PMID: 41272086

Volasertib purchased from MedChemExpress. Usage Cited in: NPJ Precis Oncol. 2025 Nov 21;9(1):373. [Abstract]

MCL17-PDX mice were treated as indicated: vehicle (n = 5), abemaciclib (50 mg/kg, oral, daily; n = 5), and volasertib (5 mg/kg, intraperitoneal, weekly; n = 5). Tumor size was measured every 7 days during the treatment. Tumor volume = length x width2/2. Mice were euthanized after 21 days of treatment. Tumors were excised and weighed in comparison between each group.
PLoS Biol

The cell cycle regulator PLK1 promotes murine melanoma progression by regulating the transcription factor BACH1. [Abstract]

2025 Nov 24;23(11):e3003490. PMID: 41284701
Cell Death Discov

CeDaD-a novel assay for simultaneous tracking of cell death and division in a single population. [Abstract]

2025 Mar 4;11(1):86. PMID: 40038265
Sci Signal

The kinase PLK1 promotes Hedgehog signaling-dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer. [Abstract]

2025 Mar 18;18(878):eadi5174. PMID: 40100956

Volasertib purchased from MedChemExpress. Usage Cited in: Sci Signal. 2025 Mar 18;18(878):eadi5174. [Abstract]

BI6727 (BI) treatment rescued the protein levels of PDCD4 resulting from nocodazole (Noc)–mediated mitotic arrest. DU145 shCtl and shPLK1 cells were generated with lentivirus expressing control shRNA or one of two specific PLK1 shRNA, followed by nocodazole (100 ng/ml) or 10 nM BI6727 treatment for 16 hours. The protein levels of PLK1 and PDCD4 were determined by immunoblotting, with β-actin and p-H3 as controls for loading and mitotic arrest. Blots are representative of three independent experiments
Mol Cancer Ther

AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer. [Abstract]

2024 Oct 1;23(10):1404-1417. PMID: 38894678
Pharmaceutics

Navitoclax Enhances the Therapeutic Effects of PLK1 Targeting on Lung Cancer Cells in 2D and 3D Culture Systems. [Abstract]

2022 Jun 6;14(6):1209. PMID: 35745782
Mol Cancer Ther

Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer. [Abstract]

2018 Apr;17(4):825-837. PMID: 29437878
Bioorg Chem

A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. [Abstract]

2022 Feb:119:105505. PMID: 34838332
Spectrochim Acta A Mol Biomol Spectrosc

Spectroscopic study on volasertib: Highly stable complexes with albumin and encapsulation into alginate/montmorillonite bionanocomposites. [Abstract]

2024 Jul 15:322:124823. PMID: 39033609
J Cell Mol Med

Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage. [Abstract]

2026 Apr;30(7):e71101. PMID: 41896195
Biochim Biophys Acta Mol Basis Dis

YAP/Aurora A-mediated ciliogenesis regulates ionizing radiation-induced senescence via Hedgehog pathway in tumor cells. [Abstract]

2024 Feb 10;1870(4):167062. PMID: 38342416
J Inflamm Res

PLK1 Mediates the Proliferation and Contraction of Airway Smooth Muscle Cells and Has a Role in T2-High Asthma with Neutrophilic Inflammation Model. [Abstract]

2025 Mar 25:18:4381-4394. PMID: 40162075
Sci Rep

Differential gene expression profiling linked to tumor progression of splenic marginal zone lymphoma. [Abstract]

2017 Sep 8;7(1):11026. PMID: 28887496
PLoS Genet

Genetic enhancers of partial PLK1 inhibition reveal hypersensitivity to kinetochore perturbations. [Abstract]

2023 Aug 28;19(8):e1010903. PMID: 37639469
J Photochem Photobiol B

Shedding light on the binding mechanism of kinase inhibitors BI-2536, Volasetib and Ro-3280 with their pharmacological target PLK1. [Abstract]

2022 Jul:232:112477. PMID: 35644070
Biochim Biophys Acta

The small molecule CS1 inhibits mitosis and sister chromatid resolution in HeLa cells. [Abstract]

2018 May;1862(5):1134-1147. PMID: 29410075
Med Oncol

Ursolic acid affects autophagy and apoptosis of breast cancer through PLK1 via AKT/mTOR signaling pathway. [Abstract]

2025 Jul 21;42(8):358. PMID: 40691672
PLoS Negl Trop Dis

Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoni. [Abstract]

2016 Jan 11;10(1):e0004356. PMID: 26751972
Dis Model Mech

A Drosophila chemical screen reveals targeting MEK and DGKa mitigates Ras-driven polarity-impaired tumour growth. [Abstract]

2023 Mar 1;16(3):dmm049769. PMID: 36861754
J Cancer

Lasiokaurin Regulates PLK1 to Induce Breast Cancer Cell G2/M Phase Block and Apoptosis. [Abstract]

2024 Mar 4;15(8):2318-2328. PMID: 38495493
Oncol Lett

PLK1 inhibition leads to mitotic arrest and triggers apoptosis in cholangiocarcinoma cells. [Abstract]

2024 May 14;28(1):316. PMID: 38807667
Arch Oral Biol

Construction of a DNA damage response-related signature for prognostication and therapeutic response prediction in head and neck squamous cell carcinoma. [Abstract]

2026 May:185:106557. PMID: 41747404
Connect Tissue Res

Activation of the mechanosensitive ion channels TRPV4 and PIEZO1 downregulates key regulatory systems in the chondrocyte mechanome. [Abstract]

2025 May 21:1-24. PMID: 40395084
Cell Physiol Biochem

Inhibition of Suicidal Erythrocyte Death by Volasertib. [Abstract]

2017;43(4):1472-1486. PMID: 29035889

Volasertib purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2017;43(4):1472-1486. [Abstract]

The addition of Volasertib (0.5-1.5 µg/mL blunts the increase of the percentage of annexin-V-binding erythrocytes following glucose deprivation, an effect reaching statistical significance at 1 and 1.5 µg/mL Volasertib.
Vet Comp Oncol

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers. [Abstract]

2026 Apr 26. PMID: 42036120
bioRxiv

2026 May 29.
Res Sq

2026 Apr 28.
bioRxiv

2026 Jan 27.
Chemrxiv

2024 Feb 8.
Oncotarget

Generation and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with MYC/ IGH and BCL6/ IGH gene arrangements and potential molecular targeted therapies. [Abstract]

2018 Sep 11;9(71):33482-33499. PMID: 30323893
University of California

2016.

Solvent & Solubility

In Vitro:

DMSO : 23.33 mg/mL (37.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6160 mL

8.0800 mL

16.1600 mL

5 mM

0.3232 mL

1.6160 mL

3.2320 mL

10 mM

0.1616 mL

0.8080 mL

1.6160 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (3.36 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Xie FF, et al. Volasertib suppresses tumor growth in cervical cancer. Am J Cancer Res. 2015 Nov 15;5(12):3548-59. [Content Brief]

[2]. Rudolph D, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.Clin Cancer Res. 2009 May 1;15(9):3094-102. Epub [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6160 mL	8.0800 mL	16.1600 mL	40.4001 mL
	5 mM	0.3232 mL	1.6160 mL	3.2320 mL	8.0800 mL
	10 mM	0.1616 mL	0.8080 mL	1.6160 mL	4.0400 mL
	15 mM	0.1077 mL	0.5387 mL	1.0773 mL	2.6933 mL
	20 mM	0.0808 mL	0.4040 mL	0.8080 mL	2.0200 mL
	25 mM	0.0646 mL	0.3232 mL	0.6464 mL	1.6160 mL
	30 mM	0.0539 mL	0.2693 mL	0.5387 mL	1.3467 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Volasertib

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

Rare Diseases Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) Volasertib

All Polo-like Kinase (PLK) Isoforms

Biological Activity

Chemical Information

Publications (38)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Volasertib

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

Rare Diseases Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) Volasertib

All Polo-like Kinase (PLK) Isoforms

Biological Activity

Chemical Information

Publications (38)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Volasertib Related Classifications

Cat. No.: HY-12137